Newer therapeutic strategies for soft-tissue sarcomas

Pharmacology & Therapeutics
Kevin Bourcier, Antoine Italiano

Abstract

Metastatic soft-tissue sarcoma (STS), a devastating disease, has a median overall survival of only 12-18 months. Until recently, therapeutic options were limited and relied primarily on the use of anthracycline-based chemotherapy. Over the past two decades, improvement in the knowledge of the biology of STS has allowed the investigation of new therapeutic strategies including new cytotoxic agents, epigenetic drugs, specific targeted therapies, and immunotherapeutic treatments.

Citations

Jun 27, 2019·Cardiovascular and Interventional Radiology·Kévin BourcierThierry de Baere
Aug 10, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Fan TangXia-Wei Wei

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.